Theranica Reaches Significant Coverage Milestone for Nerivio® Therapy in the U.S.
In a groundbreaking development for migraine patients, Theranica, a neuromodulation therapeutics company, has announced that its product Nerivio® has received insurance coverage for more than 158 million lives across the United States. This marks a pivotal moment in the landscape of migraine treatment, as it brings the FDA-cleared Remote Electrical Neuromodulation (REN) device to the same level of coverage as leading branded prescription medications. Nerivio® offers both acute and preventive treatments for migraine and has recently experienced a dramatic increase in payer support, with coverage doubling over the last 15 months.
The rise in coverage is attributed to a wave of renewed confidence by insurance providers in the clinical and economic benefits of the Nerivio® therapy. The therapy's availability has expanded significantly following decisions by a top-tier national health plan and numerous state-level policy updates that have broadened access. Today, more than half of the 314 million insured Americans now have the opportunity to utilize Nerivio® for managing their migraine symptoms.
Alon Ironi, CEO and Co-Founder of Theranica, emphasized the importance of this milestone, stating, "This expanded access to Nerivio represents a historical paradigm shift in the U.S. healthcare system, finally acknowledging the role of non-drug treatments in effective medical care." Ironi's comments highlight an evolving trend in healthcare that begins to prioritize evidence-based, non-pharmacological solutions over traditional pharmaceutical routes.
For those living with migraines—approximately 39 million Americans—this expanded coverage represents an essential movement toward greater accessibility to innovative and evidence-backed treatments. Nerivio® is notable for being the first FDA-cleared non-pharmacological migraine treatment to achieve such extensive insurance coverage outside of the Veterans Health Administration, setting a new precedent for prescribed therapeutic devices.
Dr. Noah Rosen, a leading expert in headache management and Director of the Headache Center of Northwell Health in New York, remarked on the significance of insurance coverage in influencing access to migraine care. He stated that it is critical for insurance companies to broaden the range of options available to both clinicians and patients, especially for those suffering from this debilitating neurological disorder.
As Nerivio® gains acceptance within the clinical community, it is being integrated into various treatment plans for both acute and preventive migraine care. This integration supports the device in becoming a standard option for practitioners focused on delivering effective migraine management tailored to individual patient needs. The treatment's non-invasive nature and ability to provide relief without adverse drug interactions make it a compelling choice in modern migraine care.
On top of the newly established insurance coverages, Theranica has introduced a Patient Assistance Program aimed at facilitating access for prescribed patients whose health plans do not cover Nerivio®. This initiative underscores the company's commitment to making migraine care more accessible while ensuring that cost does not serve as a barrier to treatment.
The device itself, Nerivio®, is worn on the upper arm and delivers small electrical pulses designed to trigger the body's natural pain-inhibitory pathways through Conditioned Pain Modulation (CPM). This innovative approach not only offers a drug-free solution to managing migraines but also allows patients aged eight and older to receive effective treatment via a smartphone-controlled application.
With more than 35 peer-reviewed clinical studies supporting its design and efficacy, Nerivio® showcases a strong safety profile and effective real-world outcomes. Overall, this increased accessibility to a broader range of treatment options marks an important step forward in the quest for effective migraine care.
The rise in coverage is attributed to a wave of renewed confidence by insurance providers in the clinical and economic benefits of the Nerivio® therapy. The therapy's availability has expanded significantly following decisions by a top-tier national health plan and numerous state-level policy updates that have broadened access. Today, more than half of the 314 million insured Americans now have the opportunity to utilize Nerivio® for managing their migraine symptoms.
Alon Ironi, CEO and Co-Founder of Theranica, emphasized the importance of this milestone, stating, "This expanded access to Nerivio represents a historical paradigm shift in the U.S. healthcare system, finally acknowledging the role of non-drug treatments in effective medical care." Ironi's comments highlight an evolving trend in healthcare that begins to prioritize evidence-based, non-pharmacological solutions over traditional pharmaceutical routes.
For those living with migraines—approximately 39 million Americans—this expanded coverage represents an essential movement toward greater accessibility to innovative and evidence-backed treatments. Nerivio® is notable for being the first FDA-cleared non-pharmacological migraine treatment to achieve such extensive insurance coverage outside of the Veterans Health Administration, setting a new precedent for prescribed therapeutic devices.
Dr. Noah Rosen, a leading expert in headache management and Director of the Headache Center of Northwell Health in New York, remarked on the significance of insurance coverage in influencing access to migraine care. He stated that it is critical for insurance companies to broaden the range of options available to both clinicians and patients, especially for those suffering from this debilitating neurological disorder.
As Nerivio® gains acceptance within the clinical community, it is being integrated into various treatment plans for both acute and preventive migraine care. This integration supports the device in becoming a standard option for practitioners focused on delivering effective migraine management tailored to individual patient needs. The treatment's non-invasive nature and ability to provide relief without adverse drug interactions make it a compelling choice in modern migraine care.
On top of the newly established insurance coverages, Theranica has introduced a Patient Assistance Program aimed at facilitating access for prescribed patients whose health plans do not cover Nerivio®. This initiative underscores the company's commitment to making migraine care more accessible while ensuring that cost does not serve as a barrier to treatment.
The device itself, Nerivio®, is worn on the upper arm and delivers small electrical pulses designed to trigger the body's natural pain-inhibitory pathways through Conditioned Pain Modulation (CPM). This innovative approach not only offers a drug-free solution to managing migraines but also allows patients aged eight and older to receive effective treatment via a smartphone-controlled application.
With more than 35 peer-reviewed clinical studies supporting its design and efficacy, Nerivio® showcases a strong safety profile and effective real-world outcomes. Overall, this increased accessibility to a broader range of treatment options marks an important step forward in the quest for effective migraine care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.